Thursday, 15 October 2026European Markets

NEDAP And QUADIENT Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - nedap (nedap.as) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
nedap (nedap.as) €59.80 5.26% 23.16%
quadient (qdt.pa) €19.58 3.04% 1.29%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. nedap (nedap.as)

5.26% forward dividend yield and 23.16% return on equity

nedap n.v., together with its subsidiaries, develops and supplies smart technological solutions in the netherlands, germany, rest of europe, north america, and internationally. the company provides software services that allow healthcare professionals to interconnect; hardware and software solutions for vehicle identification systems; and technological solutions for the dairy farming and pig farming industries. it also offers lighting solutions and uv lamp driver technologies; and rfid solutions for retailers. in addition, the company provides access control and security systems for companies and institutions. further, it offers workforce management software, a cloud-based software for timesheet processing, employee scheduling, and access control. the company was founded in 1929 and is headquartered in groenlo, the netherlands.

earnings per share

as for profitability, nedap has a trailing twelve months eps of €3.17.

pe ratio

nedap has a trailing twelve months price to earnings ratio of 18.86. meaning, the purchaser of the share is investing €18.86 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.16%.

revenue growth

year-on-year quarterly revenue growth grew by 11.1%, now sitting on 230.56m for the twelve trailing months.

volume

today's last reported volume for nedap is 373 which is 89.41% below its average volume of 3523.

moving average

nedap's value is higher than its 50-day moving average of €57.44 and above its 200-day moving average of €57.15.

volatility

nedap's last week, last month's, and last quarter's current intraday variation average was 0.79%, 0.29%, and 0.77%.

nedap's highest amplitude of average volatility was 1.01% (last week), 0.94% (last month), and 0.77% (last quarter).

more news about nedap.

2. quadient (qdt.pa)

3.04% forward dividend yield and 1.29% return on equity

quadient s.a. provides intelligent communication automation, mail-related, and parcel locker solutions for customers through digital and physical channels in north america, france, benelux, the united kingdom, ireland and germany, austria, italy, switzerland, and internationally. it provides quadient inspire, a software solution that facilitates the creation and management of transactional and marketing communication documents, as well as manages omnichannel delivery for the communications; quadient impress, a cloud-based software that facilitates outbound document automation; yaypay, account receivable process automation solutions; and beanworks, an accounts payable automation software solution. the company also offers quadient inspire flex, which enables organizations to create and deliver personalized, compliant customer communications across various channels from one centralized platform; quadient digitalboost, a suite of pre-packaged solutions that digitalizes customer processes and contracts; and quadient inspire journey, a cloud-based journey mapping solution that integrates customer journey mapping, data, and communications technologies. in addition, it supplies software, equipment, and services for managing incoming and outgoing mails; and provides hardware and software platform that facilitates invoicing and customer communications, multi-channel mail processing, last-mile parcel delivery, and the consolidation of their return. further, the company operates a pick-up, drop-off solution that offers businesses and people who need to manage their deliveries and returns. it serves financial services, healthcare, higher education, insurance, and retail industries, as well as service providers industries. the company was formerly known as neopost s.a. and changed its name to quadient s.a. in september 2019. quadient s.a. was founded in 1924 and is headquartered in bagneux, france.

earnings per share

as for profitability, quadient has a trailing twelve months eps of €1.8.

pe ratio

quadient has a trailing twelve months price to earnings ratio of 10.88. meaning, the purchaser of the share is investing €10.88 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.29%.

revenue growth

year-on-year quarterly revenue growth grew by 7.1%, now sitting on 1.08b for the twelve trailing months.

moving average

quadient's worth is higher than its 50-day moving average of €18.41 and way above its 200-day moving average of €16.28.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, quadient's stock is considered to be oversold (<=20).

more news about quadient.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com